Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized
Jason E Kemner1, H Lynn Starr, Patrick E Ciccone
1McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, Pennsylvania 19034, USA.
Advances in Therapy
|January 19, 2006
Summary
This study found OROS methylphenidate (MPH) provided greater symptom improvement for children with attention-deficit/hyperactivity disorder (ADHD) compared to atomoxetine. Both treatments were well-tolerated, with similar withdrawal rates due to adverse events.
Area of Science:
- Pediatric Psychiatry
- Neuroscience
- Pharmacology
Background:
- Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
- Effective pharmacological management is crucial for improving core ADHD symptoms and daily functioning.
- Comparative effectiveness studies in real-world settings are needed to guide clinical decision-making.
Purpose of the Study:
- To compare the treatment outcomes of OROS methylphenidate (MPH) and atomoxetine in children with ADHD.
- To evaluate physician and parent assessments of symptom improvement in a community-based setting.
- To assess the safety and tolerability of both medications.
Main Methods:
- A multicenter, prospective, open-label study randomized 1323 children (6-12 years) with ADHD to OROS MPH or atomoxetine for 3 weeks.
- Investigator-rated measures included the ADHD Rating Scale (ADHD-RS) and Clinical Global Impression-Improvement (CGI-I).
- Assessments were conducted at baseline and at weeks 1, 2, and 3.
Main Results:
- Both OROS MPH and atomoxetine significantly reduced ADHD symptoms from baseline (P < .001).
- OROS MPH demonstrated significantly greater mean reductions in ADHD-RS scores compared to atomoxetine (20.24 vs. 16, P < .001).
- Treatment response rates were significantly higher with OROS MPH at all evaluation points (P < .001), with similar adverse event-related withdrawal rates (4.8% vs. 5.5%).
Conclusions:
- OROS methylphenidate showed superior efficacy in improving ADHD symptoms compared to atomoxetine in this community-based study.
- Both medications were generally well-tolerated, suggesting they are viable treatment options for pediatric ADHD.
- The findings support OROS MPH as a potentially more effective option for symptom management in children with ADHD in a clinical practice setting.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...